Neurology · Atlanta area, GA
Neurology studies in Atlanta area, GA
71 recruiting studies have a site in the Atlanta area. This page includes nearby cities such as Decatur, Marietta, Sandy Springs, Alpharetta.
71 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
More recruiting studies (pay not posted)
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Atlanta, GA + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia
- Location
- Atlanta, GA + 17 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Atlanta, GA + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- Atlanta, GA + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 2
Study of EVO756 in Adults With Migraine
Evommune, Inc.
- Location
- Atlanta, GA + 32 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Augusta, GA + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 4
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Genentech, Inc.
- Location
- Atlanta, GA + 3 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Sundance Biosciences, Inc.
- Location
- Atlanta, GA + 2 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Decatur, GA + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Decatur, GA + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Woodstock, GA + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Atlanta, GA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Atlanta, GA + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Decatur, GA + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Pharmazz, Inc.
- Location
- Marietta, GA + 13 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2/Phase 3
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
DiaMedica Therapeutics Inc
- Location
- Atlanta, GA + 35 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Atlanta, GA + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Atlanta, GA + 13 other US sites
- Eligibility basics
- Ages 50–80
- Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
SetPoint Medical Corporation
- Location
- Atlanta, GA + 8 other US sites
- Eligibility basics
- Ages 22–60
- RecruitingPhase 2
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Zydus Therapeutics Inc.
- Location
- Atlanta, GA + 13 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company
- Location
- Decatur, GA + 4 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Atlanta, GA + 111 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
- Location
- Atlanta, GA + 39 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Atlanta, GA + 69 other US sites
- Eligibility basics
- Ages 18–80
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.